Nitin Jagannath Deshmukh
About Nitin Jagannath Deshmukh
Data last updated:
Nitin Jagannath Deshmukh is a Director at Advanced Enzyme Technologies Limited (since 2022), Director at Veeda Clinical Research Limited (since 2021) and Nominee Director at Biorad Medisys Private Limited (since 2024), and holds 4 more current directorships. The companies operate in Chemicals and Materials, Pharma and Healthcare. The 6 current companies with reported revenue have a combined latest revenue of ₹2,005 Cr; the largest is Advanced Enzyme Technologies Limited at ₹670 Cr (FY 2025). Earlier, Nitin Jagannath Deshmukh was an Additional Director at Natco Pharma Limited (2012–2014) and Director at Rubicon Research Limited (2007–2012) and 17 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Advanced Enzyme Technologies Limited L24200MH1989PLC051018 | Director | 01 Jul 2022 | 1989 | ₹670 Cr (FY 2025) | Active |
 Veeda Clinical Research Limited U73100GJ2004PLC044023 | Director | 01 Jul 2021 | 2004 | ₹621 Cr (FY 2025) | Active |
 Biorad Medisys Private Limited U33111MH2000PTC265335 | Nominee Director | 24 Dec 2024 | 2000 | ₹557 Cr (FY 2025) | Active |
 Bioneeds India Private Limited U01409KA2007PTC042282 | Director | 01 Aug 2022 | 2007 | ₹116 Cr (FY 2024) | Active |
 Gencrest Bio Products Private Limited U17309MH2020PTC340351 | Additional Director | 31 Mar 2026 | 2020 | ₹39.89 Cr (FY 2025) | Active |
 Samta Mines And Minerals Limited U14299MH2018PLC303770 | Director | 05 May 2021 | 2018 | ₹55.6 Lakh (FY 2024) | Active |
 Gencrest Private Limited U72900MH2020PTC335959 |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Natco Pharma Limited L24230TG1981PLC003201 | Additional Director | 09 Feb 2012 | 1981 | ₹4,784 Cr (FY 2025) | Active |
 Rubicon Research Limited L73100MH1999PLC119744 | Director | 25 Aug 2007 | 1999 | ₹872 Cr (FY 2024) | Active |
 Dhaanya Seeds Limited U05121KA2002PLC031204 | Nominee Director | 12 Jul 2006 | 2002 | Amalgamated | |
 Intas Biopharmaceuticals Limited U24230GJ2005PLC047111 | Director | 28 Sep 2007 | 2005 | Amalgamated | |
 Bharat Serums And Vaccines Limited U24230MH1971PLC015134 | Director | 25 Sep 2009 | 1971 | ₹1,455 Cr (FY 2023) | Amalgamated |
 Siro Clinpharm Private Limited U24230MH2000PTC125061 | Nominee Director | 28 Mar 2007 | 2000 | ₹40.18 Cr (FY 2025) | Active |
 Indus Biotech Limited U24231MH1995PLC085656 | Director | 24 Sep 2007 | 1995 | ₹71.42 Cr (FY 2025) | Active |
 Advy Biosciences Private Limited U24297MH2010PTC209352 | Additional Director | 18 Dec 2021 | 2010 | ₹195 Cr (FY 2025) | Active |
| Digitrac Power Controls Private Limited U31200TZ1992PTC004114 | Additional Director | 08 Jun 2006 | 1992 | Amalgamated | |
| Macrocomm Convergence (India) Private Limited U74210TN2002PTC049197 | Additional Director | 02 May 2006 | 2002 | Dissolved (Liquidated) |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Nitin Jagannath Deshmukh
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Nitin Jagannath Deshmukh
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nitin Jagannath Deshmukh
Nitin Jagannath Deshmukh currently holds 7 directorships: Advanced Enzyme Technologies Limited (Director, since 01 Jul 2022, revenue ₹670 Cr (FY 2025)); Veeda Clinical Research Limited (Director, since 01 Jul 2021, revenue ₹621 Cr (FY 2025)); Biorad Medisys Private Limited (Nominee Director, since 24 Dec 2024, revenue ₹557 Cr (FY 2025)); Bioneeds India Private Limited (Director, since 01 Aug 2022, revenue ₹116 Cr (FY 2024)); Gencrest Bio Products Private Limited (Additional Director, since 31 Mar 2026, revenue ₹39.89 Cr (FY 2025)); and 2 more.
Nitin Jagannath Deshmukh was first appointed on 02 Jun 2005 as Nominee Director at Metahelix Life Sciences Limited. The most recent appointment on record is 31 Mar 2026 at Gencrest Bio Products Private Limited.
The 6 current companies of Nitin Jagannath Deshmukh that report revenue have a combined latest revenue of ₹2,005 Cr: Advanced Enzyme Technologies Limited ₹670 Cr (FY 2025); Veeda Clinical Research Limited ₹621 Cr (FY 2025); Biorad Medisys Private Limited ₹557 Cr (FY 2025); Bioneeds India Private Limited ₹116 Cr (FY 2024); Gencrest Bio Products Private Limited ₹39.89 Cr (FY 2025); and 1 more.
Nitin Jagannath Deshmukh held 19 earlier board appointments: Natco Pharma Limited (Additional Director, 09 Feb 2012 to 28 Jan 2014); Rubicon Research Limited (Director, 25 Aug 2007 to 17 Dec 2012); Dhaanya Seeds Limited (Nominee Director, 12 Jul 2006 to 07 Aug 2006); Intas Biopharmaceuticals Limited (Director, 28 Sep 2007 to 11 Nov 2010); Bharat Serums And Vaccines Limited (Director, 25 Sep 2009 to 27 Sep 2016); and 14 more.
The current boards of Nitin Jagannath Deshmukh's companies include Beni Prasad Rauka (Advanced Enzyme Technologies Limited), Mukund Madhusudan Kabra (Advanced Enzyme Technologies Limited), Pradip Bhailal Shah (Advanced Enzyme Technologies Limited), Pramod Kasat (Advanced Enzyme Technologies Limited), Rasika Vasant Rathi (Advanced Enzyme Technologies Limited), Sanjay Prakash Basantani (Advanced Enzyme Technologies Limited), among others.